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Abstract
Background: In the face of impending influenza pandemic, a rapid vaccine production and mass vaccination is the most
effective approach to prevent the large scale mortality and morbidity that was associated with the 1918 ‘‘Spanish Flu’’. The
traditional process of influenza vaccine production in eggs is time consuming and may not meet the demands of rapid
global vaccination required to curtail influenza pandemic.
Methodology/Principal Findings: Recombinant technology can be used to express the hemagglutinin (HA) of the
emerging new influenza strain in a variety of systems including mammalian, insect, and bacterial cells. In this study, two
forms of HA proteins derived from the currently circulating novel H1N1 A/California/07/2009 virus, HA1 (1–330) and HA (1–
480), were expressed and purified from E. coli under controlled redox refolding conditions that favoured proper protein
folding. However, only the recombinant HA1 (1–330) protein formed oligomers, including functional trimers that bound
receptor and caused agglutination of human red blood cells. These proteins were used to vaccinate ferrets prior to
challenge with the A/California/07/2009 virus. Both proteins induced neutralizing antibodies, and reduced viral loads in
nasal washes. However, the HA1 (1–330) protein that had higher content of multimeric forms provided better protection
from fever and weight loss at a lower vaccine dose compared with HA (1–480). Protein yield for the HA1 (1–330) ranged
around 40 mg/Liter, while the HA (1–480) yield was 0.4–0.8 mg/Liter.
Conclusions/Significance: This is the first study that describes production in bacterial system of properly folded functional
globular HA1 domain trimers, lacking the HA2 transmembrane protein, that elicit potent neutralizing antibody responses
following vaccination and protect ferrets from in vivo challenge. The combination of bacterial expression system with
established quality control methods could provide a mechanism for rapid large scale production of influenza vaccines in the
face of influenza pandemic threat.
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Introduction
In April 2009, the Centers for Disease Control and Prevention
(CDC) announced the detection of a novel strain of influenza virus
in humans. The novel virus derived its genes from viruses
circulating in the pig population [1,2,3]. Due to sustained human-
to-human transmission of this novel virus throughout the world,
on June 11th the World Health Organization (WHO) raised the
worldwide pandemic alert level to Phase 6.
The most effective way to curtail pandemics is by mass
vaccination [4,5]. At the moment there are two types of licensed
vaccines against seasonal influenza in the US: subunit (split)
inactivated vaccines (IV) and live cold adapted attenuated influenza
vaccine (LAIV) [6] [7,8]. Both vaccines are grown in chicken eggs.
The process of constructing a new vaccine strain based on newly
circulating viruses is quite lengthy. It involves in vivo (in chicken
eggs) or in vitro (in cell culture using reverse genetics techniques)
reassortment between the internal genes of a donor virus such as A/
PR/8/34 with the hemagglutinin (HA) and neuraminidase (NA) of
the new influenza strain. The candidate vaccine strains must be
further selected based on their high growth capability in eggs before
they can be used for production of vaccines. Moreover, the
manufacturing process is limited in scalability by the use of eggs and
the amount of purified virus that can be produced. This process is
used for the production of seasonal influenza vaccines every year,
but it may pose a clear impediment to initiation of rapid mass
vaccination against spreading pandemic influenza, as was evident
for the 2009 H1N1 virus.
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Recombinant HA based vaccines provide an alternative that
could save several months of manufacturing time, since the HA
gene of the newly circulating strain is available shortly after virus
isolation. Expression of HA in insect cells and mammalian cells are
under development and/or clinical trials [9,10,11]. The main
challenge to the recombinant technology is to ensure that the HA
products resemble the native virion-associated trimeric spike
proteins and can elicit robust immune responses targeting
protective conformational epitopes in the globular domain of HA.
In previous studies, we constructed H5N1 whole-genome-
phage-display libraries (GFPDL) and used them to map the
antibody responses following human infection with highly
pathogenic H5N1 (A/Vietnam/1203/2004), as well as post-
H5N1 vaccination sera. We identified large HA1 fragments,
encompassing the receptor binding domain (RBD), that were
bound by broadly neutralizing human monoclonal antibodies
from H5N1 recovered individuals and by polyclonal convalescent
sera. Several HA1 fragments were expressed and purified from E.
coli inclusion bodies, and were shown to be properly folded and
presented conformational epitopes [12]. The bacterially expressed
HA1 proteins were also shown to absorb most of the neutralizing
activity in post-H5N1 infection and post-H5N1 vaccination sera
[12,13]. Based on these studies, it was predicted that HA1
fragments that contain most of the neutralizing antibody targets
may generate protective immunity against emerging influenza
strains.
Compared with insect or mammalian cells, expression of
recombinant proteins in bacteria could present a viable alternative
in terms of large scale vaccine production and a short time line
suitable for rapid response in influenza pandemic. Several studies
with bacterially expressed HA proteins based on the H5N1 avian
influenza virus (AIV) were reported [14,15,16], and one clinical
trial with a bacterially expressed fusion protein between the HA
fragment and flagellin from Salmonella typhimurium type 2 (STF2), a
TLR5 agonist is underway [17]. However, bacterially expressed
HA proteins are not subjected to the post-translational modifica-
tions that takes place in eukaryotic cells, including step-wise
glycosylation process important for proper folding of the HA
protein, as well as trimerization and transport to the cell
membrane [18,19,20]. Indeed it was argued that in the absence
of glycosylation, the newly synthesized HA proteins are not likely
to fold properly or trimerize like native HA molecules, and may
not present native conformational epitopes, which are important
for generation of an effective protective immune response. Indeed
the majority of the previous studies did not demonstrate proper
folding and/or oligomerization of the HA proteins produced in
prokaryotic systems [14,15,16,21,22]. To address this concern, we
established multiple assays to monitor the integrity of bacterially
expressed HA proteins for proper folding, formation of trimers and
oligomers, receptor binding, and agglutination of red blood cells
(RBC). Here, we describe the properties of two novel H1N1 swine-
like HA proteins, HA1 (1–330) and HA (1–480), expressed in E.
coli. Both proteins were properly folded as determined by CD
spectra, binding to post-infection and post-vaccination sera, and
could adsorbed neutralizing activity from H1N1 immune sera.
However, only the bacterially expressed HA1 globular domain (1–
330) contained functional trimers and oligomers capable of
receptor binding and RBC agglutination. Importantly, vaccination
of ferrets with both proteins resulted in reduced viral loads in nasal
washes following challenge with novel H1N1 A/California/07/
2009. However, after low dose vaccination (important for dose-
sparing in pandemic scenario), HA1 (1–330) provided better
reduction of morbidity (body temperature elevation and weight
loss) compared with HA (1–480) in vivo.
Results
Properties of bacterially expressed H1N1 HA1 (1–330)
and HA (1–480)
DNA fragments encoding amino acid sequence 1–330 and 1–
480 of HA from A/California/07/2009 were cloned as NotI-PacI
inserts in the T7 promoter based expression vector with His6 tag at
the C-terminus [13]. Both fragments of H1N1 HA expressed in E.
coli Rosetta Gami cells (Novagen) localized to insoluble fraction
(inclusion bodies). IBs were refolded in vitro under controlled redox
conditions and purified by HisTrap Fast flow chromatography.
This process was previously shown to generate highly purified
properly folded HA1 fragments from H5N1 [13]. The purified
HA1 (1–330) and HA (1–480) proteins ran as a single band on
SDS-PAGE with the anticipated MW of approximately 30 and
50 kDa, respectively (Fig. 1A).
To determine if the bacterially expressed (unglycosylated) HA1
(1–330) and HA (1–480) proteins are properly folded they were
analyzed by CD spectroscopy. The change in elipticity at 222 nm,
which monitors unfolding of a-helix structures over a range of
temperatures (CD melt), confirmed that both HA1 (1–330) and
HA (1–480) behaved as properly folded proteins with a melting
temperature around 52uC (Fig. 1 B-C).
We next determined if the bacterially expressed proteins
oligomerized into higher molecular forms, using gel filtration
chromatography on Superdex S200 XK 16/60 column (GE-
Healthcare). Surprisingly, the HA1 (1–330) protein contained at
least 50% of trimers and oligomers (Fig. 1D), while the larger HA
(1–480) contained only monomers (Fig. 1E). To further investigate
which HA forms are required for receptor binding we established
a fetuin based SPR assay that mimics the simultaneous interactions
between the virion spikes and multiple sialic acid moieties[23].
The bacterially expressed HA1 (1–330), HA (1–480), and a
mammalian cell derived recombinant full length HA (HA0) (from
Immune Technology Corp, NY) were tested for binding to fetuin
coated on biosensor chips. As shown in Fig. 1G, only HA1 (1–330)
bound efficiently to fetuin (but not to asialo-fetuin; Fig. 1F). In
contrast, neither the mammalian cell derived HA0, nor the
bacterially expressed HA (1–480) proteins bound to the fetuin in
SPR (Fig. 1G).
In addition to receptor binding, hemagglutination of red blood
cells (RBC) is a surrogate assay to measure the functionality of the
influenza hemagglutinin. The presence of trimers and oligomers
(mimicking the virion spikes) is required for the formation of RBC
lattice [24]. As seen in Fig. 1H, H1N1 virions (positive control)
agglutinated RBC very well at all the dilutions used. Bacterially
expressed H1N1 HA1 (1–330) protein (containing trimers and
oligomers) also agglutinated human RBC very efficiently, even at
the lowest concentration of 45 ng/ml. On the other hand, the
bacterially expressed HA (1–480) and mammalian cell derived
recombinant HA0 did not agglutinate human RBC. These
differences in hemagglutination were in agreement with the results
obtained in the fetuin binding SPR assay. The lack of
agglutinating capacity most likely reflected the absence of stable
trimers and oligomers in the HA (1–480) or the mammalian cell
derived HA0 protein preparations.
Bacterially expressed H1N1 HA (1–330) and HA (1–480)
and mammalian-expressed HA0 are recognized by sera
from ferrets infected with A/California/07/2009 and post
vaccination human sera
The differences in the functional properties of HA1 (1–330)
compared with the larger proteins containing the HA1+HA2
HA1 Flu Vaccine Protect Ferret
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Figure 1. Biochemical and functional characterization of bacterially expressed and purified H1N1 HA proteins. (A) Purified E. coli
derived HA proteins were analyzed by SDS-PAGE. DNA encoding HA1 (1–330) and HA (1–480) from HA gene segment of A/California/07/2009 (H1N1)
generated from egg-grown virus were used for cloning in a T7 promoter based expression vector (pSK) where the desired polypeptide can be
expressed as fusion protein with His6 tag at the C-terminus. The proteins were expressed, denatured and refolded under controlled redox conditions
and purified using His-Trap fast flow chromatography to .90% purity (see Materials and Methods). The purified proteins run at their corresponding
molecular weight in reducing SDS-PAGE. (B-C) CD melt spectroscopy shows that both H1N1 HA1 (1–330) (B) and H1N1 HA (1–480) (C) are properly
folded. Both H1N1 HA proteins, at a concentration of 0.5 mg/ml in 20 mM PBS, pH 7.2, were subjected to heating at 0.5uC/min increments. The
protein unfolding kinetics was measured at 222 nm using a J-715 Circular Dichroism system (JASCO corp., Easton, MD). (D-E) Superdex S-200 gel
filtration chromatography of purified H1N1 HA proteins from E.coli. The panels present superimposed elution profiles of purified HA proteins (red
line) overlaid with calibration standards (grey line). (D) The H1N1 HA (1–330) protein purified from bacterial cells existed as approximately 20% high-
molecular-mass oligomer (.600 kDa), 45% trimer (,110 kDa) and 35% monomer (34kDa) (red line). (E) H1N1 HA (1–480) is present only as a
monomer (50kDa). (F-G) Binding kinetics of purified H1N1 HA proteins in a SPR based receptor binding assay. Steady-state equilibrium
analysis of different H1N1-HA proteins to fetuin and its asialylated counterpart (Asialo-fetuin) was analyzed at 25uC using a ProteOn surface plasmon
HA1 Flu Vaccine Protect Ferret
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ectodomain needed further investigation. It was important to
confirm that all three proteins expressed conformational ‘‘native’’
antigenic epitopes, recognized by antibodies elicited by H1N1
infection or by immunization with traditional (inactivated) vaccine.
Ferrets are a good animal model for influenza virus pathogenesis.
Following H1N1 infection, ferrets undergo transient loss of body
weight, elevation in body temperature, and extensive viral
replication in the upper and lower respiratory track on days 1–
5, followed by viral clearance and recovery between Days 7–14
[25]. In the current study, consecutive post-H1N1 infection sera
were evaluated for virus neutralizing antibody titers in a
microneutralization assay (MN) (Fig. 2A) and for binding to
recombinant H1N1 HA proteins by surface plasmon resonance
(SPR), using either mammalian cell expressed HA0 or the
bacterially expressed H1N1 HA1 (1–330) and HA (1–480) proteins
(Fig. 2B–D). MN titers in the ferret sera were ,20 during the first
5 days, followed by a rapid rise on days 7 and 14, and started to
decline there after (Fig. 2A). On the other hand, using SPR, HA
binding antibodies were measured as early as day 5 post infection
and peaked on day 14. Importantly, binding of post-H1N1
infection ferret sera to HA0 from mammalian cells and to the
bacterially expressed HA1 (1–330) and HA (1–480) proteins
demonstrated similar kinetics and binding avidity profiles (Fig. 2
B-C-D), confirming that the bacterially expressed proteins were
antigenically similar to the mammalian cell derived HA. The
significant increase in binding to H1N1-HA proteins on days 7
and 14 correlated with the appearance of neutralizing antibodies
against A/California/07/2009 (Fig. 2A). We also evaluated the
binding of pre-and post-vaccination sera from two individuals that
were immunized with a licensed inactivated subunit A/California/
7/2009 vaccine (Fig. 2 E-F-G). Post-vaccination sera bound to
mammalian-expressed HA0 (Fig. 2E) and to bacterially-expressed
HA1 (1–330) (Fig. 2F) & HA (1–480) (Fig. 2G) proteins. The SPR
results confirmed that all three proteins were properly folded and
expressed native conformational epitopes. Interestingly, in both
ferret and human studies, antibody binding to the HA1 (1–330)
(containing trimers) was superior to that observed with the
mammalian cell derived HA0 and the bacterially expressed HA
ectodomain proteins (Fig. 2C vs. 2B and 2D, and Fig. 2F vs. 2E
and 2G).
Properly folded bacterial H1N1 HA proteins adsorb
neutralizing activity in post-H1N1 vaccination and post-
H1N1 infection sera
The functional relevance of binding to properly folded
bacterially expressed H1N1-HA proteins was further confirmed
in adsorption experiments (Table 1). Both bacterially expressed
HA1 (1–330) and HA (1–480) proteins and the mammalian cell
derived HA0 adsorbed most of the neutralizing activity of H1N1
hyperimmune sheep sera (NIBSC), reducing the MN titer from
1:6,400 to ,1:40 (Table 1, top panel). Similar results were
obtained with post-H1N1 infection ferret sera from day 21. The
H1N1-HA1 (1–330) reduced the neutralizing activity of the
convalescent sera from 1:1,280 to ,1:40. In the case of HA0
(mammalian) and bacterial HA (1–480), residual neutralizing
activity (1:80) was observed after sera adsorption (Table 1, lower
panel).
The combined data from the CD melt, SPR-based binding
assays, and adsorption studies demonstrated that both bacterially
expressed proteins are properly folded and express antigenically
relevant conformational neutralizing epitopes. However, only the
HA1 globular domain but not the HA ectodomain (or the
mammalian cell expressed HA0) contained functional trimers and
oligomers required for fetuin binding and RBC agglutination.
Immunization of rabbits and sheep with bacterially
expressed H1N1 HA1 (1–330) and HA (1–480) and
mammalian HA0 proteins
To evaluate the immunogenicity of the bacterially expressed
proteins, we immunized rabbits after mixing of HA1 (1–330) or
HA (1–480) with Titermax adjuvant. The pre- and post
vaccination sera were evaluated by microneutralization assay.
Even after a single immunization with HA1 (1–330), rabbits had a
MN titer of 1:40. After second and third immunizations high MN
titers were measured (6,400 and 25,600, respectively) (Table 2, top
panel). The HA (1–480) elicited H1N1 neutralizing antibodies
only after the second and third boosts, and the peak MN titers
(3,200 and 6,400, respectively) were lower compared with the
HA1 (1–330) immunized rabbits. In a separate study, sheep were
vaccinated with mammalian derived HA0 (Immune Technology
Corps) or with the bacterially–expressed HA1 (1–330) (Table 2,
bottom panels). Again, the kinetics of immune responses and the
peak neutralization titers were significantly higher for the sheep
immunized with the bacterially-expressed HA1 (1–330) protein
compared with the mammalian HA0 expressed and purified from
293 cells.
Vaccination and challenge studies in ferrets
The protective immunity elicited by bacterially expressed
proteins was further evaluated in a ferret challenge model [25].
Female Fitch ferrets (n = 4 in each group) were vaccinated
intramuscularly in the quadricep muscle on day 0 and boosted
on day 21 with either HA1 (1–330) or HA (1–480) proteins at 7.5
and 30 mg dose combined with Titermax adjuvant. Serum samples
were collected after vaccinations and analyzed in HAI (Fig. 3). The
30 mg dose induced 2–4 fold higher titers compared with the
7.5 mg dose for both bacterially expressed proteins (Fig. 3).
However, at the lower dose of 7.5 mg, the HA1 (1–330)
consistently elicited higher HAI titers compared with the HA (1–
480) at the same dose. The observed HAI titers measured in the
current study were similar to data from recently reported ferret
vaccination studies in which commercially available live attenu-
ated or split-inactivated licensed vaccines were used [26,27].
Following second vaccination, ferrets were challenged intrana-
sally with 16106 50% egg infectious doses (EID50) (,16105.75
TCID50/ml) of A/California/07/2009 virus in a volume of one
milliliter. To determine viral loads in nasal washes, each ferret was
administered each day post-challenge with 1.5 ml of 0.9% saline
to each nare and washes were collected for virus titer
determinations using the plaque assay.
resonance biosensor (BioRad Labs). Samples of purified H1N1-HA proteins (10 mg/ml) were injected simultaneously over a mock surface to which no
protein was bound, followed by the Asialofetuin in (F) or Fetuin in (G) immobilized on a sensor chip through the free amine group, and onto a blank
flow cell, free of protein. Binding kinetics and data analysis were performed using ProteOn system surface plasmon resonance biosensor instrument
(BioRad Labs, Hercules, CA). (H) Agglutination of human RBCs by properly folded bacterial H1N1 HA (1–330) protein. Serial dilutions of purified HA
proteins or virus were mixed with washed RBC and incubated to analyze the receptor binding and cross-linking of human RBC. Virus H1N1xPR8 A/
California/07/2009 (X-179A) was used as a control. Strong hemagglutination was observed for bacterial H1N1 HA (1–330) but not with either bacterial
H1N1 HA (1–480) or mammalian H1N1 HA0.
doi:10.1371/journal.pone.0011548.g001
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In unvaccinated animals (naı¨ve), viral loads in the nasal washes
were highest on day 1, gradually declining on days 3 and 5
(Fig. 4A) and were back to baseline on day 7 as previously
described[25]. Among the vaccinated animals, the high dose
groups (30 mg), receiving either HA1 (1–330) or HA (1–480),
reduced viral titers by .2 logs as early as day 1 post challenge. In
the 7.5 mg vaccinated animals, virus replication on day 1 was
observed, followed by a more rapid decline compared with the
unvaccinated animals (Fig. 4A). Between day 3 and 5, a more
rapid virus clearance was observed in the HA1 (1–330) vaccinated
groups compared with the HA (1–480) vaccinated group or the
naı¨ve group (Fig. 4A).
In terms of morbidity, sustained elevation in body temperatures
were measured in the naı¨ve group post H1N1 virus challenge
between days 1–4 (Fig. 4B). Inactivity and weight loss were also
recorded up to day 7, followed by a slow recovery that did not
reach normal weights by day 13 (termination) (Fig. 4C and data
not shown). The HA1 (1–330) vaccinated animals that received
30 mg protein showed no temperature elevation and no weight loss
(Fig. 4B-C). The 7.5 mg HA (1–330) vaccine dose also showed no
weight loss and only a brief mild increase in body temperature on
Day 2 (Fig. 4B-C). The HA (1–480) vaccinated animals at the
30 mg dose also showed no weight loss, and a transient elevation in
body temperature on days 1–3 (not as high as in the naive group).
But the animals that received HA (1–480) at the lower dose
(7.5 mg) showed an increase in body temperature similar to the
naı¨ve group and some weight loss on days 2–6 post challenge.
Together, these data demonstrate that properly folded bacte-
rially expressed unglycosylated H1N1 HA proteins, elicited high
neutralizing antibody titers in ferrets, not different from previously
reported antibody responses against licensed influenza vaccines
([26,27]. Importantly, at the lower vaccine dose of 7.5 mg, the
HA1 (1–330) that contained both trimers and oligomers protected
ferrets from morbidity more efficiently than the HA (1–480),
which only contain monomers. The clinical symptoms correlated
with the observed HAI titers prior to challenge.
Discussion
The recent 2009-H1N1 swine-like virus influenza pandemic
highlighted the need to rapidly produce enough vaccine doses for
global vaccination brought to light the shortcomings of the
traditional process of manufacturing influenza vaccines and the
need to use alternative approaches for a more rapid generation of
vaccine for global immunization in response to impending
influenza pandemic. Bacterially expressed HA proteins can be
Figure 2. Development of neutralizing and anti-HA binding antibodies following wt H1N1 (A/California/7/2009) infection in ferrets
& post-H1N1 vaccination (inactivated vaccine) in humans. (A)Microneutralization of H1N1 A/California/2009 virus with post-H1N1-
infected ferret samples. End-point titers (mean of three replicates) using post-infection sera from multiple ferrets at each time point in a
microneutralization assay performed with A/California/07/2009 (X-179A). For day 21, sera of ten animals were pooled. Each dot in other time-points
represents an individual H1N1 infected ferret. (B–D) Antibody kinetics following H1N1 challenge in ferrets. Steady-state equilibrium analysis
of post-H1N1 infected ferret sera or pre- & post-H1N1 vaccinated human sera to mammalian H1N1 HA0 (Immune Technologies, NY) and properly
folded bacterially expressed H1N1 HA1 (1–330) or H1N1 HA (1–480) fragment were measured using SPR. Ten-fold diluted individual post-infection
sera from each time point, were injected simultaneously onto recombinant mammalian H1N1 HA0 in (B) and properly folded bacterially expressed
H1N1 HA1 (1–330) in (C) or H1N1 HA (1–480) in (D), immobilized on a sensor chip through the free amine group, and onto a blank flow cell, free of
peptide. SPR binding of pre-vaccine and post-H1N1 vaccination sera from two individuals with different neutralizing antibody titers (in parenthesis) is
shown with recombinant mammalian H1N1 HA0 in (E) and properly folded bacterially expressed H1N1 HA1 (1–330) in (F) or H1N1 HA (1–480) in (G).
Binding was recorded using ProteOn system surface plasmon resonance biosensor instrument (BioRad Labs, Hercules, CA).
doi:10.1371/journal.pone.0011548.g002
Table 1. Adsorption of neutralization activity using HA
proteins.
Sheep anti-A/California/07/2009 -HA-sera (NIBSC)
Peptides added TITER*
No peptide 6400
HA 1–330 - FLOW-THROUGH ,40
HA 1–480 - FLOW-THROUGH ,40
Mammalian HA0 - FLOW-THROUGH ,40
GST-His - FLOW-THROUGH 6400
Ferret anti-A/California/07/2009 -infected sera
No peptide 1280
HA 1–330 - FLOW-THROUGH ,40
HA 1–480 - FLOW-THROUGH 80
Mammalian HA0- FLOW-THROUGH 80
GST-His - FLOW-THROUGH 1280
*End-point titers (mean of three replicates) using polyclonal rabbit sera in a
microneutralization assay performed with A/California/07/2009 (X-179A).
doi:10.1371/journal.pone.0011548.t001
Table 2. Mean reciprocal neutralizing titers of Rabbit and
Sheep anti-HA sera.
RABBIT SERA END-POINT TITERS*
H1N1-HA (1–330) Pre Vaccine ,20
Post- 1 40
Post- 2 6,400
Post- 3 25,600
H1N1-HA (1–480) Pre Vaccine ,20
Post- 1 ,20
Post- 2 3,200
Post- 3 6,400
SHEEP
Mammalian H1N1-HA0 Pre Vaccine ,20
Post- 1 ,20
Post- 2 1,600
Post- 3 6,400
H1N1-HA (1–330) Pre Vaccine ,20
Post- 1 80
Post- 2 12,800
Post- 3 51,200
*End-point titers (mean of three replicates) using polyclonal rabbit sera in a
microneutralization assay performed with A/California/07/2009 (X-179A).
doi:10.1371/journal.pone.0011548.t002
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manufactured rapidly and are amenable to mass production that
can fulfill global vaccine needs. The main challenge to the
prokaryotic production system is to ascertain proper refolding of
expressed HA proteins representative of native HA spike structures
on influenza virus. In addition to properly folded HA monomers,
higher MW structures (i.e., trimers and oligomers) are important
and likely to contribute to the optimal immunogenicity of the HA,
since all influenza neutralizing antibodies are conformation
dependent and some trimer specific antibodies have potent
neutralizing activity [28]. In eggs and mammalian cells, post-
translational glycosylation contribute to the proper folding,
trimerization and transport of the newly synthesized HA molecules
to the cell membrane [18]. However, in the case of recombinant
HA proteins, trimerization is not always found even in eukaryotic
cell substrates [11].
The main findings in the current study are: (a) bacterially
expressed H1N1 HA1 (1–330) and HA (1–480) can be purified as
properly folded proteins as determined by CD spectroscopy, SPR
analyses with H1N1 immune sera, and adsorption of neutralizing
activity from post-infection and post vaccination sera; (b) the HA1
(1–330) contained .50% trimeric and oligomeric forms and could
bind to fetuin and agglutinated human RBC, while the HA (1–480)
and mammalian cell expressed HA0 proteins were predominantly
monomeric, did not bind fetuin, and did not agglutinate RBC; (c)
the HA1 (1–330) induced higher titers of neutralizing antibodies
compared with HA (1–480) or mammalian derived recombinant
HA0 in rabbits and sheep; (d) in a ferret H1N1 challenge model,
high-dose vaccination (30 mg HA) with both bacterially expressed
HA1 (1–330) and HA (1–480) proteins protected animals from
morbidity (elevated body temperature and weight loss) following
challenge with novel H1N1 A/California/07/2009 virus. However,
low-dose vaccination (7.5 mg HA) of ferrets with HA1 (1–330)
resulted in lower morbidity and more rapid virus clearance
compared with the HA (1–480) vaccinated group.
This study extends our previous reports with the H5N1 highly
pathogenic virus, in which we have used whole-genome-phage
display libraries (GFPDL) to map the antibody responses following
human infection or vaccination. We have identified large HA1
fragments, encompassing the receptor binding domain (RBD), that
were bound by broadly neutralizing human monoclonal antibod-
ies from H5N1 recovered individuals and by their polyclonal
convalescent sera [12]. In a subsequent study, we found that
following vaccination with inactivated H5N1 (A/Vietnam/1203/
2004) influenza vaccine the immune sera from the MF59-
adjuvanted vaccinated individuals bound with much higher avidity
to bacterially expressed properly folded H5 HA1 proteins
compared with unadjuvanted vaccine sera [13]. Importantly, the
bacterially expressed HA1 proteins were also shown to absorb
most of the neutralizing activity in post infection and post
vaccination sera [12,13]. Based on these studies, we hypothesized
that bacterially-expressed HA1 fragments if properly folded, could
be useful as vaccines against emerging influenza strains.
In the current study, we found that expression and purification
of properly folded H1N1 HA1 (1–330) (lacking HA2) in bacterial
system was more efficient and gave higher yield compared with the
larger HA ectodomain (1–480). Between 39–45 mg of .90%
purified HA1 (1–330) protein can be obtained from 1 liter of
bacterial batch culture, while the yield for HA (1–480) was only
0.4–0.8 mg/L. In addition to the much lower yield, the HA (1–
480) contained only monomers, and as a result, it did not bind to
fetuin and did not agglutinate RBC. Both of these functions
require the presence of quartenary HA forms (i.e. trimers and
oligomers). Mammalian expressed HA0 protein exhibited the
same properties as the bacterially expressed HA(1–480) ectodo-
main. This is in agreement with previous reports on full length HA
ectodomain proteins expressed in a variety of cell substrates
wherein peptide linkers were introduced to facilitate oligomeriza-
tion [11]. Similar to our findings, the oligomerized cell-based HA
product showed better neutralizing antibodies than its monomeric
counterpart [11].
While both proteins were immunogenic in ferrets at the high
dose of 30 mg, the HA1 (1–330) was more immunogenic and
Figure 3. Hemagglutination-inhibition (HAI) titers in ferrets. HAI antibody in ferrets (n= 4 per group) vaccinated with either 30 mg or 7.5 mg
of influenza H1N1 HA1 or HA. Blood was collected at day 35 (post-dose 2). HAI responses were assessed against A/California/07/2009. Bars indicate
geometric mean titer (GMT). The titer from each individual ferret is indicated by symbol. *p= 0.05 HA (1–480) low dose vs. HA (1–480) high dose.
doi:10.1371/journal.pone.0011548.g003
HA1 Flu Vaccine Protect Ferret
PLoS ONE | www.plosone.org 7 July 2010 | Volume 5 | Issue 7 | e11548
protected ferrets from H1N1 morbidity more efficiently at a lower
dose (7.5 mg) compared with the HA (1–480) protein. In the case
of mass vaccination, dose sparing is likely to be of great impact.
The ability of HA1 globular domain to form trimers has not
been reported before. We have recently confirmed that bacterially
expressed HA1 globular heads from multiple influenza strains
(avian H5N1 and seasonal strains), can be produced at high yield.
In all cases the HA1 proteins contain trimers and oligomers and
agglutinate RBC. Studies to map the trimerization signal of HA1
are ongoing.
Figure 4. Viral loads and morbidity following A/California/07/2009 challenge in ferrets. (A) Viral replication of influenza A/
California/07/2009 in nasal washes following intranasal challenge. Average pfu of virus from the nasal washes of each group (4 ferrets per
group) on days 1, 3, and 5 post challenges. (B) Change in body temperature and (C) percent body weight.
doi:10.1371/journal.pone.0011548.g004
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In the face of an impending influenza pandemic, HA1 proteins
derived from the newly spreading virus can be rapidly expressed in
bacterial systems several months before the traditional approach
using vaccine strains generated via either gene reassortment or
reverse genetics, followed by adaptation to growth in eggs. With
appropriate testing methods in place to monitor proper folding
and biological activity (hemagglutination assay), this simple and
efficient approach may provide an early vaccine for large scale
production to fulfill global vaccine needs in a much shorter time
frame. Moreover, bacterially produced HA vaccines may also be
an alternative for humans with known egg allergies that cannot be
immunized with traditional influenza vaccines produced in eggs.
Materials and Methods
Expression vector and cloning of H1N1-HA1 (1–330) and
HA (1–480)
cDNA corresponding to the HA gene segment of A/California/
07/2009 was generated from RNA isolated from egg-grown virus
strain, and was used for cloning. pSK is a T7 promoter based
expression vector where the desired polypeptide can be expressed
as fusion protein with His6 tag at the C-terminus. DNA encoding
HA1 (1–330) and HA (1–480) were cloned as NotI-PacI inserts in
the pSK expression vector.
Protein expression, refolding and purification
E. coli Rosetta Gami cells (Novagen) were used for expression of
H1N1-HA1 (1–330) and HA (1–480). Following expression,
inclusion bodies (IB) were isolated by cell lysis and multiple washing
steps with 1% Triton X-100. The final IB pellets were resuspended
in denaturation buffer containing 6M Guanidine Hydrochloride
and dithioerythreitol (DTE) at final protein concentration of
10 mg/ml, and were centrifuged to remove residual debris. For
refolding, supernatants were slowly diluted 100-fold in redox folding
buffer [13]. The renaturation protein solution was dialyzed against
20 mM Tris HCl pH 8.0 to remove the denaturing agents. The
dialysates were filtered through 0.45 mm filters, and were subjected
to purification by HisTrap Fast flow chromatography. This process
was previously shown to generate highly purified properly folded
HA1 fragments from H5N1 [13].
Circular Dichroism (CD)-monitored equilibrium unfolding
experiment
To demonstrate that the bacterially expressed HA fragments are
properly folded they were analyzed by CD spectroscopy [13]. For CD
spectroscopy in solution, H1N1-HA proteins were dissolved in
20 mM PBS, pH 7.4, at 0.1 mg/ml. The change in elipticity at
222 nm (to follow unfolding of a-helices) during unfolding was
monitored using a J-715 Circular Dichroism system (JASCO). The
unfolding reaction was initiated by subjecting the protein in PBS to
1uC/min increments. The experiments were carried out in triplicate.
Gel filtration Chromatography
H1N1-HA1 (1–330) and HA (1–480) at a concentration of 5 mg/ml
were analyzed on Superdex S200 XK 16/60 column (GE-Healthcare)
pre-equilibrated with PBS, and the protein elution monitored at
280 nm. Protein molecular weight marker standards (GE healthcare)
were used for column calibration and generation of a standard curve to
identify the molecular weights of the test protein sample.
Affinity measurements by surface plasmon resonance
Steady-state equilibrium binding of post-H1N1 vaccine or post-
H1N1 infection sera was monitored at 25uC using a ProteOn
surface plasmon resonance biosensor (BioRad Labs). The H1N1-
HA proteins were coupled to a GLC sensor chip (BioRad Labs)
with amine coupling with 500 resonance units (RU) in the test flow
cells. Ten-fold dilution of animal sera (60 ml) was injected at a flow
rate of 30 ml/min (120-sec contact time). Flow was directed over a
mock surface to which no protein was bound, followed by the HA
protein coupled surface. Responses from the protein surface were
corrected for the response from the mock surface and for responses
from a separate, buffer only, injection. MAb 2D7 (anti-CCR5) and
naı¨ve ferret sera were used as a negative control antibody in the
experiments. Binding kinetics for the animal sera and the data
analysis were performed with BioRad ProteON manager software
(version 2.0.1). Similar binding studies were previously conducted
with H5N1 HA1 proteins. Human monoclonal antibodies with
conformation-dependent epitopes bound only to the properly
folded HA proteins that were purified at pH 7.2 (identical to the
current study) but not to unfolded HA1 proteins, purified at
pH 3.0 [13].
Receptor binding assay using surface plasmon resonance
Binding of different HA1 derivatives to fetuin (natural homolog
of sialic acid cell surface receptor proteins) and its asialylated
counterpart (Asialo-fetuin) was analyzed at 25uC using a ProteOn
surface plasmon resonance biosensor (BioRad Labs). Fetuin or
Asialo-fetuin (Sigma) were coupled to a GLC sensor chip with
amine coupling at 1000 resonance units (RU) in the test flow cells.
Samples of 60 ml freshly prepared H1N1-HA1, HA0, and
mammalian derived HA0 proteins at 10 mg/ml were injected at
a flow rate of 30 ml/min (120-sec contact time). Flow was directed
over a mock surface to which no protein was bound, followed by
the fetuin or asialo-fetuin coupled surface. Responses from the
protein surface were corrected for the response from the mock
surface and for responses from a separate, buffer only, injection.
Binding kinetics and data analysis were performed with BioRad
ProteON manager software (version 2.0.1).
Hemagglutination Assay
Human erythrocytes were separated from whole blood
(Lampire Biologicals). After isolation and washing, 30 ml of 1%
human RBC suspension (vol/vol in 1% BSA-PBS) was added to
30 ml serial dilutions of HA protein or influenza virus in 1% BSA-
PBS in a U-bottom 96-well plate (total volume, 60 ml). Aggluti-
nation was read after incubation for 30 min at room temperature.
Neutralizing Antibodies Adsorption with HA proteins
Five-fold diluted post-H1N1 vaccination (NIBSC) sera or post-
H1N1 infection ferret sera (500 ml) were added to 0.5 mg of
purified HA-His6 or to control GST-His6 protein, and incubated
for 1 hr at RT. Nickel-nitrilotriacetic acid (Ni-NTA) magnetic
beads (200 ml) (Qiagen) were added for 20 min at RT on end-to-
end shaker, to capture the His-tagged proteins and the antibodies
bound to them, followed by magnetic separation. Supernatants
containing the unbound antibodies were collected. The pre-and
post-adsorbed sera were subjected to virus microneutralization
assay.
Rabbit immunization and virus neutralization assays
White New Zealand rabbits were immunized three times
intramuscularly at 21-day intervals with 100 mg of purified H1N1-
HA1 (1–330) or HA 1–480) proteins with Titermax adjuvant
(Titermax Inc). Virus-neutralizing titers of pre- and post
vaccination rabbit sera were determined in a microneutralization
assay based on the methods of the pandemic influenza reference
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laboratories of the Centers for Disease Control and Prevention
(CDC). Low pathogenicity H1N1 virus, generated by reverse
genetics, was obtained from CDC (X-179A). The experiments
were conducted with three replicates for each serum sample and
performed at least twice.
Vaccination of ferrets and blood collection
Ferrets used in the study were tested to be sero-negative for
circulating seasonal influenza A (H1N1 and H3N2) and influenza
B viruses by HAI. Female Fitch ferrets (n = 4 in each group) were
vaccinated intramuscularly in the quadriceps muscle on day 0 and
boosted on day 21 and then challenged with virus on day 35.
Control animals (n = 4) were mock vaccinated with phosphate
buffered saline (PBS; pH 7.2). Each animal was vaccinated with
one of two doses (30 mg or 7.5 mg) of recombinant HA in sterile
0.9% saline. Each vaccine was mixed with the adjuvant
formulation, TiterMax (TiterMax USA, Inc, Norcross, Georgia,
US) at a 1:1 ratio. The volume for all intra-muscular vaccinations
was 0.5 ml. The first and second vaccinations were given in the left
and right hind legs, respectively. Blood was collected from
anesthetized ferrets via the anterior vena cava. The collected
blood was transferred to a tube containing a serum separator and
clot activator and allowed to clot at room temperature. Tubes
were centrifuged at 6000 rpm for 10 minutes; serum was
separated, aliquoted and stored at 28065uC. All procedures
were in accordance with the National Research Council (NRC)
Guidelines for the Care and Use of Laboratory Animals, the
Animal Welfare Act, and the Centers for Disease Control (CDC)/
National Institutes of Health (NIH) Bio- Safety Guidelines in
Microbiological and Biomedical Laboratories and approved by the
Institutional Animal Care and Use Committee (IACUC).
Infection and monitoring of Ferret
Animal experiments with virus A/California/07/2009 were
performed in the AALAC-accredited ABSL-3 enhanced facility.
Animals were infected and monitored as previously described[27]
except using 5% isofluorane anesthesia. Briefly, ferrets were
anesthetized with isofluorane and infected intranasally with 16106
50% egg infectious doses (EID50) (,16105.75 TCID50/ml) of A/
California/07/2009 in a volume of one milliliter. Animals were
monitored for temperature, weight loss, loss of activity, nasal
discharge, sneezing and diarrhea daily following viral challenge.
To determine viral load from nasal washes, 1.5 ml of 0.9% saline
was administered to each nare and the wash was collected each
day post-challenge of each ferret. Temperatures were measured
through use of an implantable temperature transponder (BMDS,
Sayre, PA) and were recorded at approximately the same time
each day. Pre-infection values were averaged to obtain a baseline
temperature for each ferret. Clinical signs of sneezing and nasal
discharge, inappetence, dyspnea, neurological signs, respiratory
distress, and level of activity were assessed daily. A scoring system
was used to assess activity level where 0 = alert and playful; 1 =
alert but playful only when stimulated; 2 = alert but not playful
when stimulated; 3 = neither alert nor playful when stimulated.
Based on the daily scores for each animal in a group, a relative
inactivity index was calculated [29].
Hemagglutinination Inhibition (HAI) assay
RDE-treated ferret sera were serially diluted in v-bottom 96-
well microtiter plates followed by the addition of 8 hemaggluti-
nation units (HAU) of influenza virus. Following an incubation of
approximately 20 minutes, 0.5% suspension of turkey RBC
(TRBC) in PBS (pH 7.2) were added and mixed by agitation.
The TRBCs were allowed to settle for 30 minutes at room
temperature and HAI titers were determined by the reciprocal
value of the last dilution of sera which completely inhibited
hemagglutination of TRBC. A negative titer was defined as 1:10.
Determination of viral loads
Viral loads in nasal washes were determined by the plaque
assay. Briefly, MDCK cells plated in 6-well tissue culture plates
were inoculated with 0.1 ml of virus-containing sample, serially
diluted in Dulbecco’s modified Eagle’s medium (DMEM). Virus
was adsorbed to cells for 1 h, with shaking every 15 min. Wells
were overlaid with 1.6% w/v Bacto agar (DIFCO, BD Diagnostic
Systems, Palo Alto, CA, USA) mixed 1:1 with L-15 media
(Cambrex, East Rutherford, NJ, USA) containing antibiotics and
0.6 mg/ml trypsin (Sigma, St. Louis, MO, USA). Plates incubated
for 5 days. Cells were fixed for 10 minutes using 70% v/v Ethanol
and then overlaid with 1% w/v crystal violet. Cells were then
washed with deionized water to visualize plaques. Plaques were
counted and compared to uninfected cells.
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